Partnered with Gilead Sciences Inc. and Sanofi, privately held Nurix Inc. has raised a $120m venture financing that will enable it to advance two wholly owned small molecule candidate that fight cancer via targeted protein modulation. The company said on 12 March the funding will take it well into 2022 and enable it to see clinical data from the two programs, both currently in preclinical development.
The San Francisco-based firm is not calling the fundraising a series C round, but has raised about $48m previously in equity financing, including a $6.2m seed funding backed by Third Rock Ventures and The Column Group in 2012. (Also see "Third Rock Launches Nurix With Ambitions Of Next-Gen Velcade" - Pink Sheet, 23 May, 2014.) More recently, Nurix netted $25
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?